Zymeworks (ZYME) Stock: Buy, Sell, or Hold?
$27.16
-1.91 (-6.57%)
âŧ
5d:
-5.48%
30d:
+9.65%
90d:
+8.12%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 09, 2026
0d
Protect ZYME Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (45%)
Quality Score
48/100
Position
FAIR
30-Day Fair Range
$25.74 â $29.63
Position: FAIR
Forward P/E & Valuation
23.9x
CHEAP
vs 51.0x historical avg
Wall Street Target
$41.93
+44.2% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$27.12 / $31.97
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: ZYME is fairly priced but lacks strong directional signals. At -22.3% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Nov 11, 2026 at $29.08 · last confirmed Nov 11, 2026
Strength: 5.5/10
Get Alerted When ZYME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$37.31
Based on 4.2% avg growth
INTRINSIC VALUE TODAY
$23.16
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZYME is currently trading at $27.16, which is considered fair relative to its 30-day fair value range of $25.74 to $29.63. From a valuation perspective, the stock is trading at a discount (Forward PE: 23.9) compared to its historical average (51.0). Remarkably, the market is currently pricing in an annual earnings decline of 22.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZYME is in a uptrend. The price is currently testing key support at $27.12. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: ZYME scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $41.93 (+44.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZYME is in a uptrend. The price is currently testing key support at $27.12. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: ZYME scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $41.93 (+44.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$25.74 -
$29.63
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
45.2%
Trading Range & Key Levels
30-Day Trading Range
$25.74 -
$29.63
Current vs Trading Range
FAIR
Support Level
$27.12
Resistance Level
$31.97
Current Trend
Uptrend
Technical data as of
Nov 12, 2026
Protect Your Profits
Holding ZYME? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.6%)
- BULLISH: Trading 44.2% below Wall St target ($41.93)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
23.93
Wall Street Target
$41.93
(+44.2%)
Revenue Growth (YoY)
828.7%
Profit Margin
16.3%
Valuation Discount vs History
-22.3% cheaper
PE vs Historical
23.9 vs 51.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-22.3%
(market-implied from PE analysis)
1-Year Target
$26.16
(-10%)
2-Year Target
$23.55
(-19%)
3-Year Target
$21.19
(-27%)
3-Yr Target (if PE normalizes)
(PE: 24â51)
$45.17
(+55%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.9, Growth: 4.4%)
$33.08
(+14%)
Base:
(SPY PE: 19.9, Growth: 4.4%)
$27.45
(-6%)
Bear:
(PE: 16.9, Growth: 4.4%)
$23.33
(-20%)
đ
Valuation based on Current Earnings
Forward PE: 21.05 | Forward EPS (Implied): $1.38
Bull Case
$35.10
(+21%)
Analyst growth 15.0%, PE expands to 22.1
Base Case
$29.07
(0%)
Market implied 0.0%, PE stable at 21.1
Bear Case
$22.24
(-24%)
Severe decline -15.0%, PE contracts to 19.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.9 to 51.0
Stabilization Target:
$61.95
(+113.1%)
PE Expansion Potential:
+113.1%
Share ZYME Analysis
Share this live ZYME analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ZYME)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits is currently flooded with bullish sentiment towards $ZYME, with one user expressing frustration towards a perceived 'loser' related to the stock.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:07 PM ET
Data refreshes hourly during market hours. Next update: 3:07 PM
Data refreshes hourly during market hours. Next update: 3:07 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$978 | 32 SELL |
|
PRAX
Praxis Precision MedicinâĻ |
STRONG BUY
21 analysts |
$650 | 32 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$296 | 24 SELL |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
STRONG BUY
20 analysts |
$31 | 48 HOLD |
|
NAMS
NewAmsterdam Pharma CompâĻ |
STRONG BUY
16 analysts |
$50 | 44 HOLD |
Advanced ZYME Option Strategies
Professional options setups generated by AI based on today's ZYME price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ZYME Research Pages
